Prima BioMed (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average – Here’s What Happened

Shares of Prima BioMed Ltd (NASDAQ:IMMP) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.44 and traded as low as $0.37. Prima BioMed shares last traded at $0.3766, with a volume of 581,594 shares changing hands.

Trending Headlines about Prima BioMed

Here are the key news stories impacting Prima BioMed this week:

• Positive Sentiment: Immutep said it will present positive interim Phase I data for IMP761, its first-in-class LAG-3 agonist antibody, at the EULAR 2026 conference, which could support the long-term pipeline story. Article Title
• Neutral Sentiment: Several law firms, including Rosen, Robbins LLP, Schall, DJS, Pomerantz, Bernstein Liebhard, and others, issued investor alerts and deadline reminders tied to an existing securities class action involving IMMP purchasers from March 24, 2025 to March 12, 2026. Article Title
• Neutral Sentiment: The lawsuit filings allege Immutep misled investors about the viability and efficacy of a drug candidate, with a lead-plaintiff deadline set for July 6, 2026. Article Title
• Negative Sentiment: One lawsuit notice described the case as stemming from an alleged “83% stock collapse,” reinforcing concerns that the company faces meaningful legal and reputational overhang. Article Title

Analyst Ratings Changes

Several research firms have recently issued reports on IMMP. Maxim Group lowered shares of Prima BioMed from a “buy” rating to a “hold” rating in a report on Friday, March 13th. Citizens Jmp lowered shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a report on Friday, March 13th. Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Finally, Robert W. Baird lowered shares of Prima BioMed from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $1.00 in a report on Friday, March 13th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $5.50.

Prima BioMed Price Performance

The business’s fifty day moving average is $0.44 and its two-hundred day moving average is $1.73.

Hedge Funds Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC increased its position in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. 2.32% of the stock is owned by institutional investors and hedge funds.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.